Bio-Rad Laboratories Inc (BIO)
285.28
+5.15
(+1.84%)
USD |
NYSE |
Apr 23, 16:00
285.46
+0.18
(+0.06%)
Pre-Market: 20:00
Bio-Rad Laboratories Enterprise Value: 7.728B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 7.728B |
| April 22, 2024 | 7.581B |
| April 19, 2024 | 7.570B |
| April 18, 2024 | 7.607B |
| April 17, 2024 | 7.887B |
| April 16, 2024 | 7.941B |
| April 15, 2024 | 8.160B |
| April 12, 2024 | 8.161B |
| April 11, 2024 | 8.486B |
| April 10, 2024 | 9.035B |
| April 09, 2024 | 9.274B |
| April 08, 2024 | 8.899B |
| April 05, 2024 | 8.849B |
| April 04, 2024 | 8.799B |
| April 03, 2024 | 8.952B |
| April 02, 2024 | 8.967B |
| April 01, 2024 | 9.260B |
| March 28, 2024 | 9.456B |
| March 27, 2024 | 9.561B |
| March 26, 2024 | 9.304B |
| March 25, 2024 | 9.320B |
| March 22, 2024 | 9.587B |
| March 21, 2024 | 9.631B |
| March 20, 2024 | 9.183B |
| March 19, 2024 | 9.188B |
| Date | Value |
|---|---|
| March 18, 2024 | 9.101B |
| March 15, 2024 | 9.104B |
| March 14, 2024 | 9.072B |
| March 13, 2024 | 9.187B |
| March 12, 2024 | 9.209B |
| March 11, 2024 | 9.410B |
| March 08, 2024 | 9.396B |
| March 07, 2024 | 9.272B |
| March 06, 2024 | 9.096B |
| March 05, 2024 | 9.030B |
| March 04, 2024 | 9.137B |
| March 01, 2024 | 9.069B |
| February 29, 2024 | 8.886B |
| February 28, 2024 | 9.013B |
| February 27, 2024 | 8.996B |
| February 26, 2024 | 9.236B |
| February 23, 2024 | 9.231B |
| February 22, 2024 | 9.245B |
| February 21, 2024 | 9.250B |
| February 20, 2024 | 9.396B |
| February 16, 2024 | 9.304B |
| February 15, 2024 | 8.967B |
| February 14, 2024 | 8.944B |
| February 13, 2024 | 8.607B |
| February 12, 2024 | 8.898B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.281B
Minimum
Oct 30 2023
23.43B
Maximum
Sep 02 2021
13.35B
Average
13.04B
Median
Feb 15 2023
Enterprise Value Benchmarks
| Agilent Technologies Inc | 41.60B |
| Bruker Corp | 12.18B |
| Azenta Inc | 1.946B |
| Harvard Bioscience Inc | 193.73M |
| Bionano Genomics Inc | 16.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 349.71M |
| Revenue (Quarterly) | 681.18M |
| Total Expenses (Quarterly) | 585.87M |
| EPS Diluted (Quarterly) | 12.14 |
| Gross Profit Margin (Quarterly) | 53.78% |
| Profit Margin (Quarterly) | 51.34% |
| Earnings Yield | -7.53% |
| Operating Earnings Yield | 4.04% |
| Normalized Earnings Yield | 3.730 |